© 2024 Corcept Therapeutics, Incorporated
Hypercortisolism Impact on Hypertension and Hyperglycemia and Beyond
Ralph A. DeFronzo • 2024 • Heart in Diabetes 2024
Posted with permission of the presenter.
Posted with permission of the presenter.
Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study
2024 • Heart in Diabetes 2024
Results From Grace, a Phase 3 Double-blind, Randomized-withdrawal Study of the Selective Glucocorticoid Receptor Modulator Relacorilant for the Treatment of Endogenous Hypercortisolism (Cushing Syndrome)
2024 • ENDO 2024
Rapid Clinical Improvements in a Patient with Difficult-to-Control Type 2 Diabetes by Addressing Underlying Hypercortisolism with Mifepristone
2024 • AACE 2024
Final Overall Survival Data From a Randomized, Open-Label, Phase 2 Study of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Combination With Nab-Paclitaxel in Patients With Recurrent Platinum-Resistant Ovarian Cancer
Colombo et al. • 2024 • SGO 2024 Congress
Difficult-to-Control Diabetes: Is Cortisol at Play?
• 2023 • Roundtable Discussion
ROSELLA (GOG-3073, ENGOT-OV72/MITO): A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Platinum-Resistant Ovarian Cancer
Lorusso et al. • 2023 • IGCS 2023 Congress
Safety, Pharmacokinetics, and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Dazucorilant in Healthy Volunteers
Donaldson et al. • 2023 • NEALS 22nd Annual Meeting
ROSELLA, GOG‑3073, ENGOT‑OV72/MITO: A Phase 3 Study of Relacorilant + Nab‑paclitaxel vs. Nab‑paclitaxel in Advanced, Platinum-resistant Ovarian Cancer
Lorusso et al. • 2023 • ESGO 2023 Congress